Biocon Biologics and Viatris Receive EC’s Approval for Kixelle (biosimilar, insulin aspart) for Diabetes Mellitus

Shots:

• The EC approval follows CHMP’s positive recommendation for Kixelle to treat DM in adults, adolescents, and children aged ≥1yr. The biosimilar has been approved as a 100 units/ml solution for injection in vial & pre-filled pen presentations
• The EC’s CMA is valid in all EU Member States as well as in the EEA countries including Iceland, Liechtenstein, and Norway
• The approval will allow affordable access to a rapid-acting insulin analog for people with diabetes in the EU

Click here ­to­ read full press release/ article | Ref: Biocon | Image: Business Standard